Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.35 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.35 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19772388 | 0.86 | PCSK9 (0.35) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL20031926 | 0.84 | PCSK9 (0.34) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL23026435 | 0.81 | CA4 (0.30) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL21778882 | 0.74 | — | — | |
| SCHEMBL23570765 | 0.73 | CA4 (0.32) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL23219870 | 0.69 | — | — | |
| SCHEMBL19380674 | 0.69 | — | — | |
| SCHEMBL14923047 | 0.68 | PCSK9 (0.35) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL21147723 | 0.66 | TRPV6 (0.41) | PCSK9CA4CA6CA5ACA7 | |
| SCHEMBL21033784 | 0.66 | AKT1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973835-B2 | Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase | THE PENN STATE RESEARCH FOUNDATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973835-B2 | Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase | PTPRO, PTPRR, PPP1R1B | PCSK9 4734/4885CA4 2181/4885CA6 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.